截至2025年12月21日，北交所挂牌公司共287家，总股本396.76亿股，流通股本253.12亿股。 从成交量上来看，上周（12月22日-12月27日），北交所周成交量为46.34亿股，环比减少6.63%；周成交金额为999.34亿元，环比上周减少11.68%。 | 项目 | 本周 | 比上周增减(%) | 本年累计 | | --- | --- | --- | --- | | 成交数量(亿股) | 46.34 | -6.63% | 2912.57 | | 成交金额(亿元) | 999.34 | -11.68% | 64311.80 | | 成交均价 (元) | 21.57 | -5.41% | 22.08 | 上周（12月22日-12月27日），北证50指数周跌1.19%至1463.04点。北证50成分股中，28只上涨，0只平盘，22只下跌。 其中，曙光数创（920808）涨幅居首，上涨8.75%，富士达（920640）居次，上涨5.38%。天力复合（920576）跌幅居首，下跌6.38%，则成电子（920821） 居次，下跌4.88%。 新股发行方面，12月22日-12月27日，北交所有1家公司挂牌、1 ...

Core Viewpoint - Puang Medical is advancing its listing process on the Beijing Stock Exchange, having received the first round of review inquiries, with plans to raise approximately 395 million yuan for various projects, including smart manufacturing and R&D in minimally invasive medical devices [1] Group 1: Company Overview - Established in 2013, Puang Medical specializes in the R&D, production, and sales of medical devices for diabetes care, general drug infusion, and minimally invasive interventions, targeting chronic disease treatments [1][2] - The company has been recognized as a national-level "specialized and innovative" small giant enterprise and has received multiple awards for its technological innovations [2] Group 2: Product and Market Position - The main products include diabetes care devices, general drug infusion devices, and minimally invasive intervention devices, with a focus on safety, minimally invasive procedures, and patient comfort [2][3] - The insulin pen needle is the company's core product, accounting for 65.80% of its main business revenue in 2024, and the company is a key player in both domestic and international markets [3][4] Group 3: Industry Trends and Future Outlook - The puncture intervention industry is characterized by high technical barriers and complex production processes, with a trend towards high-end, intelligent, safe, minimally invasive, and painless solutions [3][6] - With the issuance of the first review inquiry letter, the company is at a critical stage in its listing process, which, if successful, will enhance its production capabilities and R&D levels in the puncture intervention field [5][6]